Insider Selling: Prothena Co. PLC Insider Sells 8,000 Shares of Stock (PRTA)
Prothena Co. PLC (NASDAQ:PRTA) Insider Karin L. Walker sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $21.58, for a total value of $172,640.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on PRTA shares. Analysts at Ladenburg Thalmann initiated coverage on shares of Prothena Co. PLC in a research note on Thursday, May 22nd. They set a “buy” rating and a $36.50 price target on the stock. Separately, analysts at Wedbush upgraded shares of Prothena Co. PLC to a “best ideas list” rating in a research note on Friday, April 25th. Finally, analysts at Citigroup Inc. reiterated a “buy” rating on shares of Prothena Co. PLC in a research note on Thursday, April 24th. They now have a $60.00 price target on the stock. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $42.30.
Shares of Prothena Co. PLC (NASDAQ:PRTA) traded up 1.63% on Friday, hitting $21.78. 238,550 shares of the company’s stock traded hands. Prothena Co. PLC has a 1-year low of $9.46 and a 1-year high of $49.24. The stock’s 50-day moving average is $24.04 and its 200-day moving average is $29.04. The company’s market cap is $477.1 million. Prothena Co. PLC also was the target of a large drop in short interest in May. As of May 15th, there was short interest totalling 540,293 shares, a drop of 29.2% from the April 30th total of 763,327 shares. Based on an average trading volume of 505,078 shares, the short-interest ratio is currently 1.1 days. Approximately 2.5% of the company’s stock are short sold.
Prothena Co. PLC (NASDAQ:PRTA) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.81 by $0.03.
Prothena Corporation PLC is an Ireland-based, clinical-stage biotechnology company. The Company is engaged in discovering and developing monoclonal antibodies that are directed towards misfolded proteins or improper cell adhesion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.